

REMARKS

Claims 1- 13, 15, 16 and 18-30 are pending in the application. Claim 17 has been canceled and claim 14 has been canceled in this amendment. Claims 1-9 and 18-29 have been withdrawn.

Claim 10 has been amended by deleting the article “a” occurring before “brain-derived” and “nerve growth factor.” This claim has also been amended by inserting the phrase “for regenerating periodontal tissues” after “neurotrophic factor” in line 2. Support for this amendment can be found in the Specification in paragraphs [0020] – [0023]. Claim 10 has been further amended by inserting “, per tooth or defect of furcation,” immediately after “effective amount” in line 2. Support for this can be found in claim 30. The phrase “a biodegradable protein material” replaces “an absorbent material” in line 3; support for this amendment can be found in the Specification in paragraph [0059]. Lastly, the subject matter of claim 14 has been incorporated into claim 10.

No new matter has been added.

Rejections Under 35 USC § 112, Second Paragraph

The Examiner has rejected claim 10 as vague and indefinite for recitation of the phrases “a brain-derived neurotrophic factor” and “a nerve growth factor.” The Examiner contends that use of the article “a” in these phrases make it unclear whether a broad class of neuotrophic factors is being claimed or simply “brain-derived neurotrophic factor” and “nerve growth factor.”

Applicants have deleted the article “a” from claim 10, as suggested by the Examiner, thereby overcoming the rejections.

The Examiner has rejected claims 10 and 30 for recitation of “a periodontal transplant which comprises a therapeutically effective amount of a neurotrophic factor” without specifying what the therapeutically effective amount is effective to do.

Applicants have amended the claims to clearly indicate the treatment use of the therapeutic amount, thereby overcoming the rejections.

The Examiner has rejected claim 30 for lack of antecedent basis for the phrase “wherein the therapeutically effective amount is in the range of 1 X 10-12 to 1 X 10-3 g per tooth or defect of furcation.” Applicants have amended claim 10 to include “per tooth or defect of furcation,” thereby overcoming the rejection.

Rejections Under 35 USC § 112, First Paragraph (Enablement)

The Examiner has rejected claim 14 for recitation of the term “prevents” and failing to enable the use of the invention to fully prevent apical invasion of gingival epithelium along the dental root surface.

Applicants have canceled claim 14, thereby obviating the rejection.

Rejections Under 35 USC § 103

The Examiner has rejected claims 10-13, 15, 16 and 30 as obvious over Kirker-Head in view of Wikesjö, Tsuboi et al., Jurihara et al. and Harada et al. The Examiner contends that Kirker-Head teaches that BMPs are useful for treatment of periodontal disease including regeneration of periodontal ligament, bone, cementum and gingiva and suggests to the skilled artisan that a periodontal transplant containing a growth factor and an absorbent material is capable of regenerating the periodontal ligament, bone, cementum and repair dentine formation and maintain pulp vitality. The Examiner admits that Kirker-Head does not suggest that BMP-2 regenerates alveolar bone when combined with an absorbable collagen matrix, but relies on Wikesjö’s report regarding PGA-TMC/BMP-2 to fill this void. The Examiner also admits that

the Kirker-Head reference does not teach a transplant comprising BDNF and here contends that the teachings of Tsuboi et al., Jurihara et al. and Harada et al. provide the teaching omitted by Kirker-Head. Nonetheless, the Examiner concludes that the instant invention is obvious over a combination of the cited references. Applicants respectfully traverse.

One of skill in the art would not have been motivated to combine the cited references to obtain the claimed invention. In addition, even if the skilled artisan decided to try such a combination, they would not have had a reasonable expectation of success in generating the instant invention.

As stated in the accompanying Declaration, while the Kirker-Head reference includes a sentence on page 77 which states “the BMP’s ability to enhance periodontal tissue regeneration has been studied,” the Kirker-Head reference actually discloses effects of BMP-2 on skeletal tissue formation, not on periodontal tissue.

In addition, the secondary reference on which the Examiner relies, Wikesjö, does not convince the skilled artisan that periodontal tissue can be regenerated using the Wikesjö methods because ankylosis is produced in the process. The Wikesjö reference itself acknowledges this fact. Furthermore, all but one of the six references which mention ankylosis that are cited by Kirker-Head in support of the statement on page 77 indicate that ankylosis was present after treatment with BMPs. This is important because periodontal tissue regeneration is understood by those of skill in the art to exclude ankylosis, as noted in the Declaration.

Given that the data presented for the effect of BMPs on regeneration of periodontal tissue showed the presence of ankylosis, and that significant research time and effort had been invested in exploring the effect of BMPs on periodontal tissue, the skilled artisan would have had little motivation to substitute a neurotrophic factor for the BMP. While the Tsuboi et al., Kurihara et al. and Harada et al. references make general statements as to the expression of neurotrophic factors in periodontal tissues, no definitive examples showing the criticality of BDNF or other neurotrophic factors is shown. Consequently, while a skilled artisan might arguably try replacing BMPs with a neurotrophic factor because it is expressed in periodontal tissues, there would have

been no expectation of success associated with producing a periodontal transplant that would regenerate normal periodontal tissues comprising both hard tissues and soft tissues.

Lastly, there is no teaching in the references suggesting that only particular types of bioabsorbable carriers are capable of accomplishing the goal of regenerating normal periodontal tissue. As can be seen from the experiment presented in the Declaration, while PLGA is a bioabsorbable carrier, it is incapable of regenerating periodontal tissue. Thus, the finding that the combination of a neurotrophic factor and a biodegradable protein material can effect regeneration of normal periodontal tissue was not predictable from the prior art references and is nonobvious over the cited art.

In view of the above, Applicants respectfully request reconsideration and removal of the rejection.


Conclusion

Applicants submit that all of the claims define non-obvious, patentable subject matter. Reconsideration of the rejections and allowance of the claims are respectfully requested.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: November 24, 2009

Respectfully submitted,

By 
Gerald M. Murphy, Jr.
Registration No.: 28,977
BIRCH, STEWART, KOLASCH & BIRCH, LLP
8110 Gatehouse Road
Suite 100 East
P.O. Box 747
Falls Church, Virginia 22040-0747
(703) 205-8000
Attorney for Applicant

#47,604

Attachments: Declaration Submitted Under 37 C.F.R. § 1.132

PATENT
0230-0245PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

APPLICANT: Hidemi KURIHARA et al. CONF: 2459

SERIAL NO.: 10/571,069 GROUP: 1649

FILED: December 7, 2006 EXAMINER: C. M. Borgeest

FOR: THERAPEUTIC AGENT AND THERAPEUTIC METHOD FOR
PERIODONTAL DISEASES AND PULPAL DISEASES

DECLARATION SUBMITTED UNDER 37 C.F.R. § 1.132

Honorable Commissioner
Of Patents and Trademarks
P.O. Box 1450
Alexandria, VA 22313-1450

November 24, 2009

Sir:

I, Dr. Hidemi KURIHARA of the Department of Periodontal Medicine, Division of
Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima
University, Japan, do hereby declare the following:

I have attached a copy of my curriculum vitae to this Declaration.

I am Professor and chair of Department of periodontal medicine and have
worked in this field for 30 years.

I am one of the inventors of the above referenced patent application.

I am familiar with the application, as well as the development, usages and
properties of polymer compounds.

I have read and understand the subject matter of the Office Action of June 24,
2009.

The following comments are offered in support of the patentability of the instant invention.

The Examiner states that the Kirker-Head reference makes obvious the 10/571,069 application when combined with the Wikesjö, Tsuboi et al., Kurihara et al. and Harada et al. references. It seems that the Examiner is arguing that when combined, these references suggest making a periodontal transplant containing a neurotrophic growth factor and an absorbent material to treat periodontal disease. I disagree.

First, I believe that it is important to clearly understand the teachings of the various references. With this in mind, I would like to first call attention to the fact that while the Kirker-Head reference includes a sentence "the BMP's ability to enhance periodontal tissue regeneration has been studied," the reference actually discloses effects of BMP-2 on skeletal tissue formation.

Next, the Wikesjö reference includes a description on page 635 regarding cementum regeneration which states "limited cementum regeneration was observed for PGA-TMC/rhBMP-2 and PGA-TMC control sites." From our observation of the figures and tables in the Wikesjö reference, however, periodontal tissue regeneration was not successfully achieved. It is evident from the data of week 8 post-surgery (see Tables 1 and 2) and week 24 post-surgery (see Tables 3 and 4) that there were 100% ankylosis and root resorption. Figure 7 also shows ankylosis. Furthermore, the Wikesjö reference states on page 635 that "ankylosis compromised regeneration in sites receiving PGA-TMC/rhBMP-2." Therefore, although MBP-2 combined with an appropriate carrier material could potentially be used for supporting alveolar bone formation, it also appears to cause a healing aberration of periodontal tissue as a whole due to ankylosis (i.e. a bony attachment without restoration of pericementum and cementum) caused by BMPs.

Periodontal tissue regeneration by definition means reconstituting healthy periodontal tissue, i.e. to restore normal periodontal tissues including cementum, alveolar bone,

periodontal ligament and so on, at a site where periodontal tissue had been missing without any indication of ankylosis. Consequently, although the cited journal references seemingly imply that BMP enhances periodontal tissue regeneration, they actually do not provide a plausible result to show that periodontal tissue regeneration was achieved in a true sense. To the skilled artisan reading the references, the results shown do not support normal periodontal tissue regeneration – quite the opposite. That is, neither the Kirker-Head reference nor the Wikesjö reference teach regeneration of the periodontal tissue including a complex of both soft and hard tissues.

This is in contrast to the information and data presented in application 10/571,069, which has achieved periodontal tissue regeneration in a true sense. Here the inventors have obtained *in vitro* data to show that a neurotrophic factor such as BDNF enhances generation of collagen in soft tissues and have further shown through *in vivo* data that alveolar bone as well as cementum and periodontal ligament were regenerated without the occurrence of ankylosis.


It seems that the Examiner also thinks that the invention described in application 10/571,069 is obvious because the Kirker-Head reference teaches that sponges imbued with BMPs enhance osseointegration and strengthen bone as well as regenerate periodontal tissues, and that BDNF is among the known options that could be used instead of BMPs to treat periodontal disease. But the effect produced by BDNF when combined with an appropriate carrier material is more subtle than the Examiner implies, and this effect is not disclosed or suggested by the teachings of Tsuboi, Kurihara and Harada which indicate that BDNF could be used instead of BMPs.

For example, while Tsuboi and Kurihara each indicate the ability of BDNF to enhance proliferation or DNA synthesis of periodontal ligament cells, these references are silent with respect to any action of BDNF on the growth of gingival epithelium cells. However application 10/571,069 discloses that while a neurotrophic factor such as BDNF induces proliferation of periodontal ligament cells, it does not induce proliferation of gingival epithelium cells, and thus inhibits invasion of epithelium into a lesion of periodontal

tissue defect. This growth of periodontal ligament, when accompanied by inhibition of epithelium invasion, means that a neurotrophic factor such as BDNF contributes to maintaining space for the recovery of a normal periodontal tissue state. This information, which is critical to the 10/571,069 application, is not disclosed in any of the references; that is, none of the cited references disclose that neurotrophic factors, including BDNF, are effective in regenerating normal periodontal tissues comprising both hard tissues and soft tissues.

In addition, having a bioresorbable material combined with an active ingredient (i.e. a neurotrophic factor such as BDNF) is also important for the periodontal transplant to effectively exert its function to regenerate periodontal tissues and to reduce the apical invasion of gingival epithelium along the dental root surface. For example, when poly(lactic-co-glycolic acid) [PLGA] was used as a carrier, periodontal tissue regeneration was not observed (see Figure 1).

Fig.1 BDNF(50 μ g/ml)+PLGA



Periodontal tissue regeneration was not observed.

The disclosure of the 10/571,069 application shows that biodegradable protein materials provide the advantageous effect of producing normal regenerated periodontal tissue. On the other hand, Wikesjö appears to suggest that any space-providing, bioabsorbable carrier material is suitable, even though the tissue regenerated using PGA-TMC is not normal.

To summarize, it is my opinion that the skilled artisan would not have had a reasonable expectation of success in producing a periodontal transplant capable of regenerating normal periodontal tissues without ankylosis by combining the references cited by the Examiner in the Office Action of June 24, 2009.

The undersigned hereby declares that all statements made herein based upon knowledge are true, and that all statements made based upon information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

DATED: Nov. 24, 2009


Dr. (Hidemi KURAHARA)

BIOGRAPHICAL SKETCH

Name : Hidemi Kurihara Sex : Male
Date and place of birth : 15 November 1954, Chiba, Japan
Nationality : Japanese
Position title : Professor
Department of Periodontal Medicine
Division of Frontier Medical Science
Graduate School of Biomedical Sciences
Hiroshima University
Mailing address : 1-2-3, Kasumi, Minami-ku
Hiroshima 734-8553, Japan
E-mail address: hkuri@hiroshima-u.ac.jp

(1) Educational background:

Institution and location	Degree	Year	Field
Hiroshima University, School of Dentistry	D.D.S.	1980	Dentistry
Okayama University, Dental School	Ph.D.	1992	Periodontology, Microbiology

(2) Scientific bibliography

1. Fatty acid composition in phenol extracts from *Actinomyces* species, *J Dent Res*, 61:1282-1286, 1982.
2. Amphipathic antigen from *Actinomyces viscosus*, *FEMS Microbiol Lett*, 21:267-269, 1984
3. Serum immunoglobulin G antibody to periodontal bacteria, *Adv Dent Res*, 2:339-345, 1988.
4. Purification and characterization of two major outer membrane proteins from *Porphyromonas gingivalis*, *Dentistry in Japan*, 27:29-34, 1990.
5. A family study of a mother and daughter with increased susceptibility to early-onset periodontitis: microbiological, immunological, host defensive and genetic analyses, *J Periodontol*, 61:755-765, 1990.
6. Isolation and partial characterization of a 39 kDa major outer membrane protein of *Actinobacillus actinomycetemcomitans* Y4, *FEMS Microbiol Lett*, 77:85-90, 1991.
7. Monoclonal antibody to a specific antigen from *Wolinella recta* ATCC 33238, *FEMS Microbiol Lett*, 82:33-36, 1991.
8. Molecular cloning and sequence analysis of an antigen gene *tdpA* of *Treponema denticola*, *Infect Immun*, 59:1941-1947, 1991.
9. Humoral immune response to an antigen from *Porphyromonas gingivalis* 381 in periodontal disease, *Infect Immun*, 59:2758-2762, 1991.
10. Interleukin-8 is a major neutrophil chemotactic factor derived from cultured human gingival fibroblasts stimulated with interleukin-1 β or tumor necrosis factor alpha, *Infect Immun*, 60(12):5253-5258, 1992.
11. Effect of Ca $^{2+}$ on the binding of *Actinobacillus actinomycetemcomitans* leukotoxin and the cytotoxicity to promyelocytic leukemia HL-60 cells, *Biochem Mol Biol Int*, 29(5):899-905, 1993.
12. Antigenic properties of *Campylobacter rectus* (*Wolinella recta*) major S-layer proteins, *FEMS Microbiol Lett*, 108:275-280, 1993.
13. Calcium-dependent protein kinase C activity of neutrophils in localized juvenile periodontitis, *Infect Immun*, 61(8):3137-3142, 1993.
14. Abnormal proportion of $\gamma\delta$ T cells in peripheral blood is frequently detected in patients with periodontal disease, *J Periodontol*, 64(10):963-967, 1993.
15. Association of *Actinobacillus actinomycetemcomitans* leukotoxin with nucleic acids on the bacteria cell surface, *Infect Immun*, 61(11):4878-4884, 1993.
16. Assessment of interleukin-6 in the pathogenesis of periodontal disease, *J Periodontol*, 65(2):147-153, 1994.
17. Role of cytokine in the induction of adhesion molecules on cultured human gingival fibroblasts, *J Periodontol*, 65(3):230-235, 1994.
18. Leukocyte adhesion molecules CD11/CD18 and their role in periodontal diseases; In Molecular Pathogenesis of

Periodontal Disease (Genco, R., Hamada, S., Lehner, T., McGhee, J., Mergenhagen, S., editors.), American Society for Microbiology, Washington D.C., pp. 215-233, 1994.

19. Acute necrotizing ulcerative gingivitis- Risk factors involving host defense mechanisms -, Periodontology 2000, 6:116-124, 1994.
20. Molecular cloning of the S-layer protein gene of *Campylobacter rectus* ATCC 33238, FEMS Microbiol Lett, 116:13-18, 1994.
21. Isolation and characterization of a 53 kDa major cell envelope protein antigen from *Treponema denticola* ATCC 35405., J Periodontal Res, 29:70-78, 1994.
22. The inhibition of interferon- γ -induced upregulation of HLA-DR expression on cultured human gingival fibroblasts by interleukin-1 β or tumor necrosis factor- α ., J Periodontol, 65:336-341, 1994.
23. Unique intronic variations of HLA-DQ β gene in early-onset periodontitis., J Periodontol, 65:379-386, 1994.
24. Heat shock protein 60 (Gro EL) from *Porphyromonas gingivalis* : Molecular cloning and sequence analysis of its gene and purification of the recombinant protein, FEMS Microbiology Lett, 119: 129-136, 1994.
25. Risk factors of periodontal disease involving host defense mechanisms-A case report of acute necrotizing ulcerative periodontitis-, New Zealand Soc Periodontol, 77: 28-33, 1994.
26. An atypical site in HLA-DQB1 detected in leprosy patients., Int J Lepr, 62:293-294, 1994.
27. Biochemical properties of the major outer membrane proteins of *Porphyromonas gingivalis*., Microbrios, 77:247-252, 1994.
28. Molecular basis of leukocyte adhesion molecules in early-onset periodontitis patients with decreased CD11/CD18 expression on leukocytes., J Periodontol, 65:949-957, 1994.
29. Cytokine-dependent synergistic regulation of interleukin-8 production from human gingival fibroblasts., J Periodontol, 65:1002-1007, 1994.
30. Prostaglandin E₂ inhibits interleukin-6 release but not its transcription in human gingival fibroblasts stimulated with interleukin-1 β or tumor necrosis factor- α ., J Periodontol, 65:1122-1127, 1994.
31. Clinical, microbiological and host defense parameters associated with a case of localized prepubertal periodontitis., J Clin Periodontol, 22:56-62, 1995.
32. Expression of the hepatocyte growth factor gene during chick limb development, Dev Dyn, 202:80-90, 1995.
33. A microbiological and immunological study of endodontic-periodontic lesions, J Endodontics, 21:617-621, 1995.
34. The response of human gingival fibroblasts to prostaglandins., J Periodontal Res, 30:303-311, 1995.
35. Studies on the phenotypic and functional characterization of peripheral blood lymphocytes from patients with early-onset periodontitis., J Periodontol, 66:391-396, 1995.
36. Clinical and laboratory studies on a patient with rapidly progressive periodontitis and their family members. A case report., J Periodontol, 66: 403-412, 1995.
37. Distribution of black-pigmented *Prevotella* and *Porphyromonas* species in the dentition of moderate periodontitis patients., Microbial ecology in health and disease, 8: 159-169, 1995.
38. Immunological, genetic, and microbiological study of family members manifesting early-onset periodontitis, J Periodontol, 67:254-263, 1996.
39. Host defensive functions in a family manifesting early-onset periodontitis, J Periodontol, 67: 433-442, 1996.
40. New attachment to periodontally diseased root surfaces treated with hydrochloric acid, Oral Medicine and Pathology, 1: 23-28, 1996.
41. HLA class II genotypes associated with early-onset periodontitis: DQB1 molecule primarily confers susceptibility to the disease, J Periodontol, 67(9): 888-894, 1996.
42. Glucose-mediated alteration of cellular function in human periodontal ligament cells., J Dent Res, 75(9): 1664-1671, 1996.
43. Study on the interleukin-2 producing capacity of peripheral mononuclear cells in patients with periodontitis., J Clin Periodontol, 24: 44-50, 1997.
44. The regulatory effect of fermentable sugar levels on the production of leukotoxin by *Actinobacillus actinomycetemcomitance*, FEMS Microbiology Letters, 146: 161-166, 1997.

45. Characterization of *Bacteroides forsythus* Isolates, J Clin Microbiol, 35 (6): 1378-1381, 1997.
46. Host defensive, immunological, and microbiological observations of an early-onset periodontitis patient with virus-associated hemophagocytic syndrome, J Periodontol, 68: 1223-1230, 1997.
47. Molecular cloning and characterization of the gene encoding 53 kDa outer membrane protein of *Porphyromonas gingivalis*, Microblos 92: 47-57, 1997.
48. Differential effects of various growth factors and cytokines on the synthesis of DNA, type I collagen, laminin, fibronectin, osteonectin/SPARC and alkaline phosphatase by human pulp cells in culture, Journal of Cellular Physiology, 174: 194-205, 1998.
49. Immunocytochemical and immunochemical study of emamelins, using antibodies against porcine 89-kDa enamelin and its N-terminal synthetic peptide, in porcine tooth germs, Cell Tissue Res. 293:313-325, 1998.
50. T cell responses to 53-kDa outer membrane protein of *Porphyromonas gingivalis* in humans with early-onset, Human Immunology 59:635-643, 1998.
51. The cell cycle-specific growth-inhibitory factor produced by *Actinobacillus actinomycetemcomitans* is a cytolethal distending toxin, Infect Immune 66(10): 5008-5019, 1998.
52. Molecular cloning and characterization of rat trp homologues from brain, Molecular Brain Research 64: 41-51, 1999
53. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells, Journal of Bone and Mineral Research 14: 1486-1492, 1999.
54. Platelet-activating factor in gingival crevicular fluid from periodontitis patients as a potential clinical disease activity marker, Journal of the International Academy of Periodontology 1:60-64, 1999.
55. Adherence of *Bacteroides forsythus* to host cells, Microblos, 101: 115-126, 2000.
56. Effects of ageing on proliferative ability, and the expression of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells, Mech. Ageing Dev. 117: 69-77, 2000.
57. Mediation by platelet-activating factor of 12-hydroxyeicosatetraenoic acid-induced cytosolic free calcium concentration elevation in neutrophils, Prostaglandins & other Lipid Mediators 62: 385-394, 2000.
58. Defective calcium influx factor activity in neutrophils from Patients with localized juvenile periodontitis, J.Periodontol 71: 797-802, 2000.
59. Immunodetection of noncollagenous matrix proteins during periodontal regeneration, J Periodont Res, 30 : 205-213, 2001.
60. Expression of IL-1b and IL-8 by human gingival epithelial cells in response to *Actinobacillus actinomycetemcomitans*. Cytokine 14(3): 152-161, 2001.
61. Transforming growth factor-b1 and basic fibroblast growth factor modulate osteocalcin and osteonectin/SPARC syntheses in vitamin D-activated pulp cells, J. Dent. Res., 80(7), 1653-1659, 2001.
62. Clinical periodontal findings and microflora profiles in children with chronic neutropenia under supervised oral hygiene, J Periodontol, 2001 Jul; 72(7): 945-952.
63. Nitric oxide synthase activity in neutrophils from patients with localized aggressive periodontitis, J Periodontol. 2001 Aug.; 72(8): 1052-1058.
64. Immunodetection of noncollagenous matrix proteins during periodontal tissue regeneration, J Periodontal Res. 2001 Aug;36(4):205-13.
65. Identification of six major outer membrane proteins from *Actinobacillus actinomycetemcomitans*, Gene. 2002 Apr 17;288(1-2):195-201.
66. Osteoprotegerin levels increased by interleukin-1beta in human periodontal ligament cells are suppressed through prostaglandin E2 synthesized de novo, Cytokine. 2002 May 7; 18(3): 133-139.
67. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells, J. Oral Pathol. Med. 2002 Jul; 31(6):345-352.
68. Microbiological, immunological, and genetic factors in family members with periodontitis as a manifestation of systemic diseases, associated with hematological disorders, J Periodont Res, 2002 Aug; 37(4), 307-315.
69. Effects of transforming growth factor-beta 1 and fibronectin on SPARC expression in cultures of human periodontal ligament cells, Cell Biol Int. 2002;26(12):1065-72.

70. Neurotrophins in cultured cells from periodontal tissues, *J Periodontol.* 2003 Jan.; 74(1):76-84.
71. Proliferative ability and alkaline phosphatase activity with in vivo cellular aging in human pulp cells, *J Endod.* 2003 Jan;29(1):9-11.
72. Enhancement of alkaline phosphatase synthesis in pulp cells co-cultured with epithelial cells derived from lower rabbit incisors, *Cell Biol Int.* 2003;27(10):815-23.
73. Immunohistochemical characteristics of epithelial cell rests of Malassez during cementum repair, *J Periodontal Res.* 2003 Feb;38(1):51-6.
74. The effect of extracellular calcium ion on gene expression of bone-related proteins in human pulp cells, *J Endod.* 2003 Feb;29(2):104-7.
75. Prevalence of cytolethal distending toxin production in periodontopathogenic bacteria, *J Clin Microbiol.* 2003 Apr;41(4):1391-8.
76. Expression of endothelins and their receptors in cells from human periodontal tissues, *J Periodontal Res.* 2003 Jun;38(3):269-75.
77. Macrophage inflammatory protein-3alpha and beta-defensin-2 stimulate dentin sialophosphoprotein gene expression in human pulp cells, *Biochem Biophys Res Commun.* 2003 Jul 11;306(4):867-71.
78. *Staphylococcus aureus* susceptibility to innate antimicrobial peptides, beta-defensins and CAP18, expressed by human keratinocytes, *Infect Immun.* 2003 Jul;71(7):3730-9.
79. Differential gene expression of bone-related proteins in epithelial and fibroblastic cells derived from human periodontal ligament, *Cell Biol Int.* 2003;27(7):519-24.
80. Outer membrane protein 100, a versatile virulence factor of *Actinobacillus actinomycetemcomitans*, *Mol Microbiol.* 2003 Nov;50(4):1125-39.
81. Syntheses of prostaglandin E2 and E-cadherin and gene expression of beta-defensin-2 by human gingival epithelial cells in response to *Actinobacillus actinomycetemcomitans*, *Inflammation.* 2003 Dec;27(6):341-9.
82. An N-terminal segment of the active component of the bacterial genotoxin cytolethal distending toxin B (CDTB) directs CDTB into the nucleus, *J Biol Chem.* 2003 Dec 12;278(50):50671-81.
83. Differential effects of growth factors and cytokines on the synthesis of SPARC, DNA, fibronectin and alkaline phosphatase activity in human periodontal ligament cells, *Cell Biol Int.* 2004;28(4):281-6.
84. Expression of the gene for Dec2, a basic helix-loop-helix transcription factor, is regulated by a molecular clock system, *Biochem J.* 2004 382:43-50.
85. Enhancement of periodontal tissue regeneration by transplantation of bone marrow mesenchymal stem cells. *J Periodontol.* 2004 Sep;75(9):1281-1287.
86. Effect of bone morphogenetic proteins-4, -5 and -6 on DNA synthesis and expression of bone-related proteins in cultured human periodontal ligament cells. *Cell Biol Int.* 2004;28(10):675-682.
87. Characterization of epithelial cells derived from periodontal ligament by gene expression patterns of bone-related and enamel proteins. *Cell Biol Int.* 2005 Feb;29(2):111-117.
88. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β -defensins and LL37, produced by human epithelial cells. *J Antimicrob Chemother.* 2005 Jun;55(6):888-896. Epub 2005 May 10.
89. Molecular markers distinguish bone marrow mesenchymal stem cells from fibroblasts. *Biochem Biophys Res Commun.* 2005 Jun 24;332(1):297-303.
90. Irsogladine maleate influences the response of gap junctional intercellular communication and IL-8 of human gingival epithelial cells following periodontopathogenic bacterial challenge. *Biochem Biophys Res Commun.* 2005 Jul 29;333(2):502-507.
91. Characteristics of periodontal ligament subpopulations obtained by sequential enzymatic digestion of rat molar periodontal ligament. *Bone.* 2005 Oct 18; [Epub ahead of print]
92. Brain-derived neurotrophic factor enhances periodontal tissue regeneration. *Tissue Eng.* 2005 Sep-Oct; 11(9-10):1618-1629.
93. Nikawa H, Egusa H, Makihira S, Okamoto T, **Kurihara H**, Shiba H, Amano H, Murayama T, Yatani H, Hamada T. An in vitro evaluation of the adhesion of *Candida* species to oral and lung tissue cells. *Mycoses.* 2006 Jan;49(1):14-17.

94. Iwata T, Kawamoto T, Sasabe E, Miyazaki K, Fujimoto K, Noshiro M, **Kurihara H**, Kato Y. Effects of overexpression of basic helix-loop-helix transcription factor Dec1 on osteogenic and adipogenic differentiation of mesenchymal stem cells. *Eur J Cell Biol*. 2006 May;85(5):423-431.

95. Mizuno N, Shiba H, Ozeki Y, Mouri Y, Niitani M, Inui T, Hayashi H, Suzuki K, Tanaka S, Kawaguchi H, **Kurihara H**. Human autologous serum obtained using a completely closed bag system as a substitute for foetal calf serum in human mesenchymal stem cell cultures. *Cell Biol Int*. 2006 Jun;30(6):521-524.

96. Xu WP, Mizuno N, Shiba H, Takeda K, Hasegawa N, Yoshimatsu S, Inui T, Ozeki Y, Niitani M, Kawaguchi H, Tsuji K, Kato Y, **Kurihara H**. Promotion of functioning of human periodontal ligament cells and human endothelial cells by nerve growth factor. *J Periodontol*. 2006 May;77(5):800-807.

97. Hasegawa N, Kawaguchi H, Hirachi A, Takeda K, Mizuno N, Nishimura M, Koike C, Tsuji K, Iba H, Kato Y, **Kurihara H**. Behavior of transplanted bone marrow-derived mesenchymal stem cells in periodontal defects. *J Periodontol*. 2006 Jun;77(6):1003-1007.

98. Fujita T, Ashikaga A, Shiba H, Uchida Y, Hirono C, Iwata T, Takeda K, Kishimoto A, Hirata R, Kawaguchi H, Shiba Y, **Kurihara H**. Regulation of IL-8 by Irsogladine maleate is involved in abolishment of *Actinobacillus actinomycetemcomitans*-induced reduction of gap-junctional intercellular communication. *Cytokine*. 2006 Jun;34(5-6):271-277.

99. Ouhara K, Komatsuzawa H, Shiba H, Uchida Y, Kawai T, Sayama K, Hashimoto K, Taubman MA, **Kurihara H**, Sugai M. *Actinobacillus actinomycetemcomitans* outer membrane protein 100 triggers innate immunity and production of beta-defensin and the 18-kilodalton cationic antimicrobial protein through the fibronectin-integrin pathway in human gingival epithelial cells. *Infect Immun*. 2006 Sep;74(9):5211-5220.

100. Nishikubo S, Ohara M, Ikura M, Katayanagi K, Fujiwara T, Komatsuzawa H, **Kurihara H**, Sugai M. Single nucleotide polymorphism in the cytolethal distending toxin B gene confers heterogeneity in the cytotoxicity of *Actinobacillus actinomycetemcomitans*. *Infect Immun*. 2006 Dec;74(12):7014-7020.

101. Fujita T, Iwata T, Shiba H, Igarashi A, Hirata R, Takeda K, Mizuno N, Tsuji K, Kawaguchi H, Kato Y, **Kurihara H**. Identification of marker genes distinguishing human periodontal ligament cells from human mesenchymal stem cells and human gingival fibroblasts. *J Periodontal Res*. 2007 Jun;42(3):283-286.

102. Igarashi A, Segoshi K, Sakai Y, Pan H, Kanawa M, Higashi Y, Sugiyama M, Nakamura K, **Kurihara H**, Yamaguchi S, Tsuji K, Kawamoto T, Kato Y. Selection of Common Markers for Bone Marrow Stromal Cells from Various Bones Using Real-Time RT-PCR: Effects of Passage Number and Donor Age. *Tissue Eng*. 2007 Oct;13(10):2405-2417.

103. Mizuno N, Shiba H, Xu WP, Inui T, Fujita T, Kajiyama M, Takeda K, Hasegawa N, Kawaguchi H, **Kurihara H**. Effect of neurotrophins on differentiation, calcification and proliferation in cultures of human pulp cells. *Cell Biol Int*. 2007 Dec;31(12):1462-1469.

104. Komatsuzawa H, Ouhara K, Kawai T, Yamada S, Fujiwara T, Shiba H, **Kurihara H**, Taubman MA, Sugai M. Susceptibility of periodontopathogenic and cariogenic bacteria to defensins and potential therapeutic use of defensins in oral diseases. *Curr Pharm Des*. 2007;13(30):3084-95. Review.

105. Fuse Y, Hirata I, **Kurihara H**, Okazaki M. Cell adhesion and proliferation patterns on mixed self-assembled monolayers carrying various ratios of hydroxyl and methyl groups. *Dent Mater J*. 2007 Nov;26(6):814-9.

106. Fujita T, Ashikaga A, Shiba H, Kajiyama M, Kishimoto A, Hirata R, Tsunekuni N, Hirono C, Kawaguchi H, Shiba Y, **Kurihara H**. Irsogladine maleate counters the interleukin-1 beta-induced suppression in gap-junctional intercellular communication but does not affect the interleukin-1 beta-induced zonula occludens protein-1 levels in human gingival epithelial cells. *J Periodontal Res*. 2008 Feb;43(1):96-102.

107. Kajiyama M, Shiba H, Fujita T, Ouhara K, Takeda K, Mizuno N, Kawaguchi H, Kitagawa M, Takata T, Tsuji K, **Kurihara H**. Brain-derived Neurotrophic Factor Stimulates Bone/Cementum-related Protein Gene Expression in Cementoblasts. *J Biol Chem*. 2008 Jun 6;283(23):16259-16267.

108. Kishimoto A, Fujita T, Shiba H, Komatsuzawa H, Takeda K, Kajiyama M, Hayashida K, Kawaguchi H, **Kurihara H**. Irsogladine maleate abolishes the increase in interleukin-8 levels caused by outer membrane protein 29 from *Aggregatibacter (Actinobacillus) actinomycetemcomitans* through the ERK pathway in human gingival epithelial cells. *J Periodontal Res*. 2008 Oct;43(5):508-513.

109. Mizuno N, Shiba H, Inui T, Takeda K, Kajiyama M, Hasegawa N, Kawaguchi H, **Kurihara H**. Effect of neurotrophin-4/5 on bone/cementum-related protein expressions and DNA synthesis in cultures of human periodontal ligament cells. *J Periodontol*. 2008 Nov;79(11):2182-2189.

110. Mizuno N, Ozeki Y, Shiba H, Kajiya M, Nagahara T, Takeda K, Kawaguchi H, Abiko Y, **Kurihara H**. Humoral factors released from human periodontal ligament cells influence calcification and proliferation in human bone marrow mesenchymal stem cells. *J Periodontol*. 2008 Dec;79(12):2361-2370.

111. Shiba H, Tsuda H, Kajiya M, Fujita T, Takeda K, Hino T, Kawaguchi H, **Kurihara H**. Neodymium-doped yttrium-aluminium-garnet laser irradiation abolishes the increase in interleukin-6 levels caused by peptidoglycan through the p38 mitogen-activated protein kinase pathway in human pulp cells. *J Endod*. 2009. Mar;35(3):373-376.

(3) Honors and awards:

1985-present, Councilor, The Japanese Society of Conservative Dentistry
1992-present, Councilor, The Japanese Society of Periodontology
1992 The grant from Ryobi Teien Memorial Foundation
1994 The grant from Kobayashi Magobe Memorial Medical Foundation
1995 The first prize of Award in research section of 5th IAP meeting
1997 The fourth prize of Award in research section of 6th IAP meeting
2005 One of the top ten downloaded papers of Biochemical Communications in 2005, Elsevier Pub.
2006-present, Executive Director, Japanese Association for Dental Science
2006-present Executive director, Japan Endodontic Association
2007-present, Vice President, The Japanese Society for Evidence and the Dental Professional
2009 R. Earl Robinson Periodontal Regeneration Award, American Academy of Periodontology

(4) Member of editorial boards:

Journal of the Japanese Society of Periodontology
Journal of Dental Research, 1999-2003

(5) Appointments

2000-2002, Vice director, Hiroshima University Dental Hospital
2002-2003, Director, Hiroshima University Dental Hospital
2003-2004, Vice director, Hiroshima University Hospital
2004-2008, Dean, Faculty of Dentistry, Hiroshima University
2008-2009, Vice Executive (Community Collaboration), Hiroshima University